Skip to main content

One-Third With Transient New-Onset A-Fib Have Recurrence

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

MONDAY, Oct. 2, 2023 -- About one-third of participants with transient new-onset atrial fibrillation (AF) during hospitalization for noncardiac surgery or medical illness have recurrent AF within one year, according to a study published online Oct. 3 in the Annals of Internal Medicine.

William F. McIntyre, M.D., Ph.D., from McMaster University in Hamilton, Ontario, Canada, and colleagues estimated the risk for AF recurrence in patients with new-onset AF during a hospitalization for noncardiac surgery or medical illness in a matched cohort study. Patients hospitalized for noncardiac surgery or medical illness who had transient new-onset AF were enrolled and age- and sex-matched to controls with no history of AF from the same hospital ward (139 cases and 139 controls).

The researchers found that recurrent AF was detected in 33.1 and 5.0 percent of participants in the transient new-onset AF and control groups, respectively; the adjusted relative risk was 6.6. Recurrent AF was detected in 32.3 and 3.0 percent of participants with transient new-onset AF and matched controls, respectively, after exclusion of participants who had electrical or pharmacological cardioversion during their index hospitalization and their matched controls and limited to AF events detected by the patch electrocardiogram monitor.

"The risk for having AF detected is markedly higher than in matched control participants," the authors write. "Future studies are required to assess the efficacy of oral anticoagulation for stroke prevention in this population."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted October 2023

Read this next

AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours

WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

Patient–Primary Care Provider Language Concordance Tied to Better Outcomes

TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.